Astrocytes isolated from individuals with amyotrophic lateral sclerosis (ALS) are toxic to motor neurons (MNs) and play a non-cell autonomous role in disease pathogenesis. The mechanisms underlying the susceptibility of MNs to cell death remain unclear. Here we report that astrocytes derived from either mice bearing mutations in genes associated with ALS or human subjects with ALS reduce the expression of major histocompatibility complex class I (MHCI) molecules on MNs; reduced MHCI expression makes these MNs susceptible to astrocyte-induced cell death. Increasing MHCI expression on MNs increases survival and motor performance in a mouse model of ALS and protects MNs against astrocyte toxicity. Overexpression of a single MHCI molecule, HLA-F, protects human MNs from ALS astrocyte-mediated toxicity, whereas knockdown of its receptor, the killer cell immunoglobulin-like receptor KIR3DL2, on human astrocytes results in enhanced MN death. Thus, our data indicate that, in ALS, loss of MHCI expression on MNs renders them more vulnerable to astrocyte-mediated toxicity.
ALS is a fatal, adult-onset neurodegenerative disorder characterized by the progressive loss of MNs and death due to respiratory failure 1 . The majority of cases are classified as sporadic ALS (SALS), in which affected individuals have no family history of the disease. Despite efforts to identify risk factors and potential susceptibility genes, the etiology of SALS remains mostly unknown 2 . Current understanding of the cellular and molecular mechanisms underlying this disease is mostly derived from animal models bearing mutations in genes associated with autosomal dominant familial ALS (FALS) [3] [4] [5] [6] [7] . Despite the difference in etiology, FALS and SALS are phenotypically indistinguishable. Several studies have suggested a common disease mechanism for FALS and SALS 8, 9 , and therefore, knowledge gathered from animal models of FALS can help in understanding the mechanism underlying SALS 10 .
In addition to cell-intrinsic damage that occurs within MNs, glial cells such as astrocytes, microglia and oligodendrocytes contribute to MN death in ALS in a non-cell autonomous manner 11, 12 . Astrocytes derived from post-mortem biopsies of human subjects with ALS induce MN death in vitro, opening the possibility to study these patient-specific cells in great detail 13, 14 . However, the understanding of how and why MNs die in this disease remains unknown.
Recent work in development, aging and neurological disorders, including ALS, has focused on immune molecules-such as cytokines, proteins of the complement system and MHCI proteins-and their role in the developing and adult brain [15] [16] [17] . In the central nervous system (CNS), MHCI plays a role in synaptic function 15, [18] [19] [20] [21] [22] and neurodegenerative processes 23, 24 . In the SOD1 G93A mouse model of ALS, in which a disease-associated variant of human superoxide dismutase 1 (SOD1) is expressed, higher levels of MHCI on MNs have been observed in animals that have slower disease progression 25 . Furthermore, disease progression is accelerated in SOD1 G93A mice lacking β-2 microglobulin (β2m), an essential component for MHCI presentation 26 . Taken together, these findings suggest that MHCI may have a role in the pathogenesis of ALS.
RESULTS
MHCI expression is reduced on MNs in ALS MHCI molecules and β2m are enriched in mouse spinal MNs (Supplementary Fig. 1a,b) . To examine changes in MHCI expression on MNs in ALS, we analyzed MHCI expression before and after disease onset in all segments of the spinal cords of SOD1 G93A mice and compared them to those in wild-type (WT) mice. By using an antibody that recognizes subgroups of mouse MHCI (histocompatibility-2, MHC variant k (H2-K b ) and H2-D b ) and that is commonly used for MHCI detection in MNs 25, 27 , we found that MHCI expression was markedly reduced in MN somata but increased in motor axons in SOD1 G93A mice after disease onset ( Fig. 1a,b and Supplementary Fig. 1c-e ). These results are in agreement with previous findings using another rapid-progressing SOD1 mouse model (129Sv-SOD1 G93A ) showing that MHCI protein is transported away from the MN cell body and accumulates in peripheral motor axons during disease progression 25 .
Next, to determine whether the loss of MHCI in MNs observed in the mouse model is also seen in human individuals with ALS, we evaluated MHCI expression by immunohistochemistry in spinal cord samples from individuals with FALS who have the SOD1 A4V mutation and from those with SALS and compared expression to that in postmortem spinal cord samples from similarly aged individuals who had never been diagnosed with ALS (non-ALS controls). Using an antibody that recognizes human leukocyte antigen (HLA)-A, HLA-B and HLA-C, we observed that MHCI expression in MNs was nearly absent in spinal cords from individuals with FALS or SALS, as compared to that in the spinal cords of individuals without ALS ( Fig. 1c,d) .
Loss of MHCI by MNs after exposure to ALS astrocytes Using our recently described coculture system of adult CNS-derived microglia with MNs 28 , we evaluated the impact of microglia from individuals with ALS on the expression of MHCI in MNs. Although SOD1 G93A -expressing microglia (which we refer to as SOD1 G93A or ALS microglia) have been shown to be toxic to MNs 28 , we did not observe any overt changes in MHCI expression on MNs that were cocultured with SOD1 G93A microglia ( Fig. 2a) . However, coculturing MNs with SOD1 G93A -expressing (or ALS) astrocytes 29 , which were confirmed to be devoid of other glia types or cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells ( Supplementary Fig. 2a-g) , resulted in diminished expression of MHCI on MNs within 24 h, and the expression steadily declined over the next 96 h, at which point ~73% of MNs completely lost MHCI expression ( Fig. 2b) . In contrast, MNs that were cocultured with WT astrocytes showed slightly increased MHCI expression during the same period of time ( Fig. 2b) . This could reflect MN maturation in the presence of astrocytes 30 , which affects MHCI expression patterns in neurons 31 .
To evaluate whether expression of ALS-linked mutant SOD1 protein within MNs could lead to intrinsic downregulation of MHCI expression, we generated WT and SOD1 G93A MNs using induced pluripotent stem cell (iPSC) technology 32 . The iPSCs have the gene for green fluorescent protein (GFP) under the control of the MN-specific Mnx1 (also known as Hb9) promoter, thus allowing MN enrichment using a fluorescence-activated cell sorter after MN-induced cell differentiation ( Supplementary Fig. 3a,b) 32 . After confirming that both WT and SOD1 G93A iPSCs showed neuronal morphology and gene expression profiles similar to those of MNs derived from mouse embryonic stem npg cells ( Supplementary Fig. 3c ), we evaluated MHCI levels. During the first 72 h of culture, no significant change in MHCI expression was found between WT and SOD1 G93A MNs, and only a modest downregulation of MHCI was observed in SOD1 G93A MNs by 120 h ( Supplementary  Fig. 4a ). Furthermore, after co-culture with SOD1 G93A astrocytes, SOD1 G93A -expressing MNs display levels of MHCI similar to those in wild-type MNs that were co-cultured with the same SOD1 G93A astrocytes ( Supplementary Fig. 4b ), suggesting that ALS astrocytes are a main contributor to the downregulation of MHCI in MNs. Of note, the findings described above were not observed in GABAergic neurons, a neuronal population that is spared from ALS astrocyte-induced toxicity after coculture 13, 14, 33, 34 , because MHCI expression levels in these cells were found to be constant throughout the culture period in the presence of SOD1 G93A astrocytes ( Supplementary Fig. 4c ). Next, to determine whether cell-cell contact between MNs and astrocytes was required for MHCI loss in MNs to occur, we cultured MNs in medium that was previously used to culture astrocytes but without physical contact with astrocytes. As observed in the presence SOD1 G93A astrocytes, by 24 h a majority of MNs lost MHCI expression after culture with SOD1 G93A astrocyte-conditioned medium-a time point at which 95% of MNs were still alive ( Supplementary  Fig. 5a )-suggesting that ALS astrocytes secrete factors that induce MHCI downregulation in MNs. On the basis of these findings we then evaluated whether we could recapitulate this downregulation of MHCI in MNs by using compounds that act on pathways shown to be affected in ALS. Compounds causing endoplasmic reticulum (ER) stress, oxidative stress and inflammatory responses were tested. Treatment with thapsigargin, a sarco-endoplasmic reticulum calcium-ATPase inhibitor known to induce ER stress in MNs 35 , led to loss of MHCI expression in >76% of MNs, whereas treatment with menadione, an oxidative-stress inducer, and the pro-inflammatory molecules tumor necrosis factor (TNF)-α, interferon (IFN)-γ and Fig. 5b) . Taken together, these results suggest that astrocytes may secrete inducers of ER stress that result in loss of MHCI in MNs.
Levels of MHCI in MN determine susceptibility to ALS astrocyte-induced toxicity
To test the hypothesis that restoring MHCI expression to MNs may prevent astrocyte-mediated toxicity, we overexpressed three MHCI molecules in MNs before coculturing them with mouse ALS astrocytes. Mouse classical MHCI molecules of the subclasses H2-D b , H2-K b or H2-L d were overexpressed using lentiviral vectors (Lv) in sorted Mnx1-GFP-expressing MNs, resulting in the transduction of >80% of MNs and the rescue of MHCI levels on MNs exposed to SOD1 G93A astrocytes (Supplementary Fig. 6a-d) 36 . Whereas overexpression of H2-D b or H2-L d in MNs resulted in a modest increase in MN survival, overexpression of H2-K b fully protected MNs from the toxic effects of SOD1 G93A astrocytes, with no changes in cell morphology (Fig. 3a) . This effect was not due to the lentivirus infection per se, as expression of red fluorescent protein (RFP) did not alter SOD1 G93A astrocyte-mediated toxicity, with >60% MN cell death occurring after 120 h of coculture (Fig. 3b) . Short hairpin RNA (shRNA)-mediated knockdown of H2 k expression in MNs did not induce MN cell death per se or alter MN susceptibility to stress molecules (Supplementary Fig. 7a ), but it did increase susceptibility to SOD1 G93A astrocyte-induced toxicity ( Supplementary  Fig. 7b) . Notably, reduction of MHCI expression in GABAergic neurons led to a decrease in their survival after coculture with SOD1 G93A astrocytes, with an observed 43.7% cell death as compared to GABAergic neurons that were transduced with a scrambled (control) shRNA (Supplementary Fig. 7c-e ). These findings suggest that MHCI expression by neuronal cells modulates their susceptibility to ALS astrocyte-induced toxicity.
Sustained H2 k expression delays SOD1 G93A -dependent disease progression Because adenovirus-associated virus (AAV) 9 readily transduces MNs in the spinal cord after delivery into the cerebral spinal fluid (CSF) 37,38 , we constructed AAV9 vectors that encode H2-K b (AAV9-H2 k ) or H2-D b (AAV9-H2 d ) to target MNs in SOD1 G93A mice. We also used AAV9-GFP to confirm that a high level of transduction in spinal cord MNs of SOD1 G93A mice could be achieved by our delivery method (Supplementary Fig. 8a) . Treatment with AAV9-H2 k (or AAV9-H2 d ) increased H2 k (or H2 d ) mRNA expression in spinal cords (Supplementary Fig. 8b) . We observed that SOD1 G93A mice treated with AAV9-H2 k at postnatal day 1 had a 21-d extension in mean survival, as compared to littermate SOD1 G93A mice that were injected with a control vector (AAV9-empty) (156.9 ± 2.6 d for AAV9-H2 k -treated mice versus 135.5 ± 1.6 d for AAV9-empty-treated mice; Fig. 3c ). Among the AAV9-H2 k -injected mice, 39% of them survived >165 d, with the longest-living mouse surviving for 182 d. For SOD1 G93A mice that were injected with AAV9-H2 d , there was no significant (P > 0.05) change in the mean survival time, as compared to AAV9-empty-treated SOD1 G93A mice (139.2 ± 1.4 d for AAV9-H2 dtreated mice versus 135.5 ± 1.6 d for AAV9-empty-treated mice). Mean disease onset, as assessed by age at peak body weight, did not npg differ between the AAV9-H2 k -, AAV9-H2 d -and AAV9-empty-treated groups (103.3 ± 2.0 d, 103.1 ± 1.2 d and 99.73 ± 1.2 d, respectively; Fig. 3d,e) ; however, disease duration, as assessed by disease progression, was increased by 50.3% in AAV9-H2 k -treated mice, but not in AAV9-H2 d -treated mice (Fig. 3f) . Videos of SOD1 G93A mice during the disease-progression period show a marked difference between AAV9-H2 k -injected versus AAV9-empty-injected mice (Supplementary Videos 1-4) . During this stage, AAV9-H2 k -injected SOD1 G93A mice showed greater ambulatory capacity than AAV9empty-injected animals. Motor function was also improved, as assessed by the rotarod test (Fig. 3g) . The delay in disease progression for the AAV9-H2 k -treated SOD1 G93A mice is probably not derived from H2k b expression in astrocytes, as the overexpression of H2k b in SOD1 G93A astrocytes in vitro did not modify their toxicity toward MNs (Supplementary Fig. 9 ).
ALS astrocytes express MHCI inhibitory receptors
The level of MHCI expression on cells allows innate immune cells, including natural killer (NK) cells, to distinguish target cells from healthy cells 39 . Reduced presentation of MHCI antigen on target cells is a trigger for NKs to secrete effector molecules and to kill the target cells 40 . However, when target cells retain MHCI expression, NKs can sense this MHCI, leading to the engagement of signaling cascades that inhibit lymphocytic toxicity and result in the preservation of the target cells 40, 41 . To determine whether ALS astrocytes have the ability to sense MHCI levels on MNs, we examined the expression of MHCI receptors in both spinal cord and on astrocytes derived from SOD1 G93A mice. mRNA expression analysis of H2-K inhibitory receptors of the killer cell lectin-like receptor, subfamily A (Klra; also known as Ly49) family (such as Klra3 (Ly49c), Klra9 (Ly49i) and Klra23 (Ly49w)) were highly expressed on spinal cords of SOD1 G93A mice at the end stages of the disease (Fig. 4a) . Immunostaining analysis using antibodies to detect the Ly49c and Ly49i (which we refer to collectively as Ly49c/i) receptors confirmed expression of these two receptors in the ventral horn of the lumbar spinal cord of SOD1 G93A mice, with little to no expression in age-matched WT mice (Fig. 4b,c) . 96 ± 2% of Ly49c/i + cells were astrocytes (as defined by immunoreactivity of the astrocyte-specific membrane protein GLAST or the cytoplasmic protein GFAP) ( Fig. 4c and Supplementary Fig. 10a ). Ly49c/i receptors were also expressed in SOD1 G93A astrocytes that were used in our in vitro studies ( Fig. 4d,e) . These receptors were also detected in infiltrating lymphocytes that were found in the spinal cord of SOD1 G93A mice 42 ; however, lymphocyte numbers were minimal and, therefore, only accounted for a small fraction of the cells expressing the Ly49c/i receptors (Supplementary Fig. 10b ).
We extended our analysis to astrocytes derived from individuals with ALS and analyzed mRNA expression of a panel of 14 genes that encode MHCI receptors. We found that killer cell immunoglobulinlike receptor, three Ig domains and long cytoplasmic tail 2 (KIR3DL2), which encodes an inhibitory MHCI receptor, was uniquely expressed in all of the human ALS astrocyte cell lines tested (Fig. 4f) . There was no detectable expression of MHCI inhibitory receptor genes, including KIR3DL2, in the non-ALS control astrocyte cell lines investigated. We also confirmed KIR3DL2 expression in post-mortem spinal cord samples from individuals with SALS and observed that it was predominantly localized to GFAP + astrocytes (Fig. 4g,h) .
HLA-F protects human MNs from ALS astrocyte toxicity
The human MHCI molecule F (encoded by HLA-F) has been identified as a ligand that can physically and functionally interact with the KIR3DL2 receptor 43 . HLA-F is expressed in MNs of non-ALS spinal cord samples, and its expression is reduced in MNs in spinal cord samples from individuals with ALS ( Fig. 5a,b) . To test whether sustained expression of HLA-F in human MNs protects them from ALS astrocyte-induced toxicity, we used an in vitro model system in which human MNs and human astrocytes were cocultured 14 . MNs generated from human embryonic stem cells (ESCs) were found to have good neuronal morphology, good immunoreactivity to the MN markers MNX1 (or HB9), neurofilament marker (as assessed by using the SMI32 antibody) and choline acetyltransferase (ChAT), and minimal to no non-neuronal cell contamination (Fig. 5c) . Because MHCI recognition is species specific, we needed to construct a vector that could deliver HLA-F to human MNs. A lentiviral vector encoding human HLA-F, as well as an internal ribosome entry site (IRES) and enhanced GFP (eGFP) to track transduced cells, was constructed (Lv-HLA-F-IRES-eGFP). Transgene expression and high levels of MN transduction were confirmed, with a transduction efficiency of over 90% (Fig. 5d) , and all cells expressing eGFP were found to express HLA-F ( Supplementary Fig. 11 ). Three days after the MNs were transduced, astrocytes-which were devoid of contamination by other glia and CTLs (Supplementary Fig. 2d,e )-were added to the cultures. After 2 weeks we observed that overexpression of HLA-F in human MNs increased MN survival after coculture with either FALS or SALS astrocytes (Fig. 5e,f) . No change in survival was observed for HLA-F-overexpressing MNs that were cocultured with non-ALS astrocytes, suggesting a specific effect of HLA-F in preventing ALS astrocyte-mediated toxicity rather than improved general MN survival. To test whether suppression of KIR3DL2 in ALS astrocytes would enhance their toxicity toward MNs, we performed shRNA-mediated knockdown of KIR3DL2 in human astrocytes ( Supplementary  Fig. 12a ). All ALS astrocytes that were treated with a scrambled shRNA control were toxic to MNs, and we observed ~50% MN death at day 14 after incubating MNs and astrocytes together ( Supplementary  Fig. 12b ). For MNs that were cocultured with ALS astrocytes lacking KIR3DL2 expression, we observed 50% MN death at day 7 after commencing the coculture (Supplementary Fig. 12b ), suggesting that ALS astrocytes lacking the functional receptor for HLA-F show increased cytotoxic activity.
DISCUSSION
We and others have recently shown that astrocytes derived from individuals with ALS are toxic to MNs 13, 14, 44 . These findings add to the growing evidence that non-cell autonomous mechanisms contribute to MN death in ALS and point to a crucial role of glia in ALS pathogenesis 11, 12 . However, the mechanisms underlying ALS astrocyte toxicity and selectivity toward MNs remain unknown. The understanding of these mechanisms is required to develop therapies aimed at delaying or even preventing MN degeneration in ALS. Here, using the SOD1 G93A mouse model of ALS and autopsy material from human subjects with ALS, we show that ALS astrocytes recognize MNs as their targets on the basis of reduced MHCI expression on the MNs at later stages of disease. The relatively stable levels of MHCI found in GABAergic neurons after their coculture with ALS astrocytes may explain why certain neuronal subtypes other than MNs are spared from the astrocyte-mediated toxicity. Of note, ALS microglia do not cause downregulation of MHCI in MNs, but they still induce MN death 28 , suggesting that the mechanisms for MN recognition involving reduced levels of MHCI are astrocyte specific within the glial population. Overall, our findings, along with previous reports that suggest the possible involvement of MHCI in many neurologic npg a r t i c l e s 4 0 2 VOLUME 22 | NUMBER 4 | APRIL 2016 nature medicine disorders [23] [24] [25] [45] [46] [47] , support the important role of MHCI molecules in the MN degeneration that occurs in ALS. Further studies are necessary to precisely identify the signals originating from the astrocytes and the molecular mechanism for MHCI reduction in MNs after contact with the ALS astrocytes. Here we showed that soluble factors secreted from ALS astrocytes can downregulate MHCI expression on MNs and identified ER stress as a probable mechanism governing this downregulation. ER dysfunction is a critical contributor to MHCI loss on various cell types 48 . Indeed, in the SOD1 mouse models, ER stress is one of the first phenotypic alterations detected in vulnerable MNs 49, 50 , and it remains a prominent feature of post-mortem spinal cord MNs from human subjects with ALS 51 . Because MHCI downregulation may initiate cellular events that trigger ALS astrocyte toxicity, it is imperative to identify how ALS astrocytes cause ER stress in MNs. Among the potential mechanisms, misfolded SOD1 should be considered because of its known association with ER stress 35, 52 .
Our results are consistent with the finding that ALS astrocytes might develop aberrant characteristics to convey toxicity to MNs 53 . Despite this, the observation that FALS and SALS astrocytes express predominantly a single KIR3DL2 opens the possibility to find common molecules that have potential therapeutic strategy to ALS independent of disease etiology. HLA-F is a promising candidate because of its ability to interact with KIR3DL2 (ref. 43 ) and because of the low frequency of polymorphisms in HLA-F among different human populations 54 . Notably, HLA-F protein expression was found to be downregulated in MNs from post-mortem human spinal cord samples from individuals with ALS, and sustained HLA-F expression in human MNs in vitro conferred protection from toxicity mediated by both FALS and SALS astrocytes. These findings suggest that viral vectors (such as AAV9) that have been developed to treat CNS disorders [55] [56] [57] [58] [59] can be used to deliver HLA-F to MNs and hamper astrocyte toxicity in individuals with FALS or SALS.
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